Skip to Content

Aerpio Pharmaceuticals, Inc. 

Merger

  • Date:
  • 5/27/2021
  • Company Name:
  • Aerpio Pharmaceuticals, Inc.
  • Stock Symbol:
  • ARPO
  • Company Name - Buyer:
  • Aadi Bioscience, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 5/17/2021

Case Finder

Locate any case using the tools below.

NEW YORK, May 27, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Aadi Bioscience, Inc.

On May 17, 2021, Aerpio announced that it had signed an agreement to be acquired by Aadi in an all-stock merger.  Pursuant to the merger agreement, at the close of the merger Aerpio stockholders will own approximately 33.2% of the combined company, while Aadi stockholders will own 66.8%.  In addition, following the closing of a concurrent PIPE financing, Aerpio stockholders will own only 14.7% of the combined company. The deal is scheduled to close in the third quarter of 2021.

Bragar Eagel & Squire is concerned that Aerpio’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Aerpio’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aerpio Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: